WIP 2401
Alternative Names: WIP-2401Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Whanin Pharmaceutical
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Depressive disorders
Most Recent Events
- 04 Oct 2024 Early research in Depressive disorders in South Korea (unspecified route) prior to October 2024 (Whanin Pharmaceutical pipeline, October 2024)